Oncology and Hematology - Global Oncology Academy

257-272 of 651

Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
MET and Other Emerging Targets in Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®
MET and Other Emerging Targets in Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
MinuteCE®
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 credits 9 episodes
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 credits 9 episodes
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
MinuteCE®
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
MinuteCE®
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD; Paolo A. Ascierto, MD
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
HER2-Driven Strategies in Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
MinuteCE®
HER2-Driven Strategies in Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits

17/11